![](/img/cover-not-exists.png)
Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients
Rockstroh, J, DeJesus, E, Henry, K, Molina, J, Gathe, J, Wei, X, Fordyce, M, Rhee, M, Szwarcberg, JVolume:
15
Language:
english
Journal:
Journal of the International AIDS Society
DOI:
10.7448/IAS.15.6.18220
Date:
November, 2012
File:
PDF, 179 KB
english, 2012